Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 5/20 | 0.37 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.37 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.37 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.37 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.36 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.35 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.34 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | RBP4 | P02753 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14839527 | 0.89 | BCDIN3D (0.35) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| Trifluoroacetic Acid SCHEMBL14839980 | 0.76 | PRCP (0.39) | SSTR4TRPV1KDM1A | |
| Trifluoroacetic Acid SCHEMBL14829254 | 0.72 | PRCP (0.34) | SSTR4RBP4KDM1A | |
| SCHEMBL14839957 | 0.72 | TRPV1 (0.35) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| Trifluoroacetic Acid SCHEMBL14829349 | 0.71 | KDM1A (0.44) | KDM1A | |
| Trifluoroacetic Acid SCHEMBL14830108 | 0.70 | SLC6A2 (0.41) | KDM1A | |
| Trifluoroacetic Acid SCHEMBL14839831 | 0.68 | KDM1A (0.47) | KDM1A | |
| SCHEMBL25347686 | 0.68 | TRPV1 (0.36) | TRPV1CREBBPABL1 | |
| SCHEMBL25347693 | 0.68 | TRPV1 (0.36) | TRPV1CREBBPABL1 | |
| SCHEMBL30434319 | 0.68 | TRPV1 (0.36) | TRPV1CREBBPABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2751088-B1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMA (US) | 2016-04-13 | — | — | EP | disclosed |
| US-8765751-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-07-01 | — | — | US | disclosed |
| US-20130089624-A1 | Compounds Useful as Inhibitors of ATR Kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130089624-A1 | Compounds Useful as Inhibitors of ATR Kinase | ATR, CHEK1, PLK1 | SSTR4 4666/4885SSTR1 4446/4885SSTR2 4543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.